Calcipotriene
Obesity & Overweight
Hospital Universitario Dr. Jose E. GonzalezSmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Obesity & Overweight cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tirzepatide University of Bonn | Phase 4 | B |
hdm1005 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | B |
bio101 Biophytis | Phase 2 | CCC |
Dwrx5003 Daewoong Pharmaceutical Co. LTD. | Phase 1 | CC |
DWC202503 Daewoong Pharmaceutical Co. LTD. | Phase 1 | CC |
View all 14 →
Same molecule, other indications
Calcipotriene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →